WebFood and Drug Administration WebIn June 2024, the U.S. Food and Drug Administration granted accelerated approval to selinexor for the treatment of adult patients with relapsed or refractory diffuse large B …
ATIONAL DRUG ONTROL STRATEGY ERFORMANCE EVIEW …
WebApr 14, 2024 · – Updated Safety and Efficacy Data Will be Presented in a Poster Session at AACR 2024 from All Patients Enrolled in the Phase 1 Study – – Company to Host Investor Webcast Featuring a Key Opinion Leader on April 18, 2024 at 4:30 p.m. ET to Discuss Updated Results –. NEWTON, Mass. , April 14, 2024-- Karyopharm Therapeutics Inc. … Web18 hours ago · The Supreme Court on Friday temporarily blocked a federal court's ruling that suspended the FDA's approval of the abortion pill. The stay applies until 11:59 p.m. ET on Wednesday. discretionary reporting accounting
Karyopharm Announces Updated Selinexor Data in Patients with …
WebDec 7, 2024 · Overexpression of Exportin-1 (XPO1), a key regulator of nuclear-to-cytoplasmic transport, is associated with inferior patient outcomes across a range of adult malignancies. Targeting XPO1 with selinexor has demonstrated promising results in clinical trials, leading to FDA approval of its use for multiple relapsed/refractory cancers. However, XPO1 … WebApr 14, 2024 · About XPOVIO ® (selinexor). XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for ... WebMar 1, 2024 · In addition, considering the FDA's feedback, the Company intends to initiate a new placebo-controlled, randomized clinical study of selinexor in patients with p53 wild-type endometrial cancer and believes top-line data will be available in the first half of 2024. discretionary request 2022